Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know
April 22, 2016 at 10:52 AM EDT
JPMorgan’s Anupam Rama believes data from the two phase 3 trials of fostamatinib would be positive and that Rigel ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|